Milestone Pharmaceuticals Inc. Common Shares
Here’s whether Milestone Pharmaceuticals Inc. Common Shares (MIST) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.12% over 10 days); RSI 25 — oversold; weak 1-year return of -29.3%; 3-month momentum negative (-26.4%). Currently 59.8% off its 52-week high. Score: -7/7.
MIST is trading below its 200-day MA ($1.89) — a key warning sign the longer-term trend is under pressure. An RSI of 25.2 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -29.3% compares to +24.4% for SPY (trailed the market by 53.7%). The current 59.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.